The mechanism of fibrinolysis has been reviewed taking into account its two pathways extrinsic and intrinsic and the important role of α 2plasmin inhibitor. A clear distinction is now well documented on the mechanism of fibrinolysis in a liquid phase and in a solid phase.
The role of fibrin as an important trigger of fibrinolysis in vivo is demonstrated.
Finally a relationship between hypofibrinolysis and thrombosis is highly probable.
AstrupT. Fibrinolysis: an overview. In: DavidsonJFRowanRMSamamaMMDesnoyersPC, eds. Progress in Chemical Fibrinolysis and Thrombosis, Vol. IV. New York: Raven Press, 1978; 1: p 57.
2.
CashJD. Neurohumoral pathways associated with the release of plasminogen activator in man. In: DavidsonJFRowanRMSamamaMMDesnoyersPC, eds. Progress in Chemical Fibrinolysis and Thrombosis, Vol. 1. New York: Raven Press, 1975; p 97.
3.
AokiNVon KaullaKN. The extraction of vascular plasminogen activator from human cadavers and a description of some of its properties. Am J Clin Pathol, 1971; 55: 171–177.
4.
NiewiarowskiSProu-WartelleO. Rôle de facteur contact (facteur Hageman) dans la fibrinolyse. Thromb Diath Haemorrh, 1959; 3: 593–603.
5.
GriffinJGCochraneCG. Recent advances in the understanding of contact activation reactions. Seminars Thrombos Hemostas, 1979; 4: 254–273.
6.
KluftC. Levels of plasminogen activators in human plasma: New methods to study the intrinsic and extrinsic activators. In: DavidsonJFRowanRMSamamaMMDesnoyersPC, eds. Progress in Chemical Fibrinolysis and Thrombosis, Vol. 3, New York: Raven Press, 1978; p. 141.
7.
MandleRJKaplanAP. Hageman-factor dependent fibrinolysis: Generation of fibrinolytic activity by the interaction of human activated factor XI and plasminogen. Blood, 1979; 54: 850–862.
8.
HednerUAbildgaardU. Report on the joint meeting of the task forces on nomenclature and standard of inhibitors of coagulation and fibrinolysis. Thromb Haemostas, 1978; 39: 524–525.
9.
CollenD. Identification and some properties of a new reacting plasmin inhibitor in human plasma. Eur J Biochem, 1976; 69: 209–216.
10.
MoroiMAokiN. Isolation and characterization of α2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem, 1976; 251: 5956–5965.
11.
MullertzSClemmensenI. The primary inhibitor of plasmin in human plasma. Biochem J, 1976; 159: 545–553.
12.
AokiNSaitoHKamiyaTKoieKSakataYKohakuraM. Congenital deficiency of α2-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest, 1979; 63: 877–884.
ClaeysHVermylenJ. Physicochemical and proenzyme properties of NH2-terminal glutamic acid and NH2-terminal lysine human plasminogen. Influence of 6-aminohexanoic acid. Biochim Biophys Acta, 1974; 442: 351–359.
15.
ThorsenS. Human urokinase and porcine tissue plasminogen activator. Thesis. Copenhagen: Laegeforeningens Forlag, 1977.
16.
SamamaMConardJCazenaveBDerlonAGaudricACoscasG. Modifications of α2-plasmin inhibitor during treatments by a defibrinating agent. Thromb Haem, Stuttgart, 1979; 42 (1): 277 (abstract no. 655).
17.
WimanBCollenD. On the role of α2-antiplasmin in the regulation of fibrinolysis. In: CollenDWimanBVerstraeteM, eds. The Physiological Inhibitors of Blood Coagulation and Fibrinolysis. Amsterdam: Elsevier/North-Holland, 1979; p 85.
